Integra LifeSciences Holdings Corporation has announced the first implantation of its Integra® Laminoplasty System, in the United States, a product it hopes will help it garner a chunk of the rapidly growing laminoplasty market.
The Laminoplasty System is designed for use after open-door laminoplasty procedures in the cervical and thoracic spine (C3-T3). The system encompasses a variety of robust, arched plate designs, self-drilling bone screws and multiple insertion options, offering surgeons choices when treating patients with central canal stenosis and myelopathy.
The system, which is used to treat patients with ossification of the posterior longitudinal ligament, cervical myelopathy and degenerative spinal canal stenosis, was implanted by Douglas Orndorff, M.D., Orthopaedic Spine Surgeon at the Mercy Medical Center in Durango, Colorado.
With the addition of the Integra® Laminoplasty System, Integra says it is well positioned to gain a key foothold in the rapidly growing market, which it estimates will reach approximately $70 million by 2015
“Integra’s Laminoplasty system provides surgeons with a versatile solution for treatment of central canal stenosis,” said Dr. Orndorff. “The patient presented with progressive cervical myelopathy, had lordotic cervical alignment, and no neck pain. She was the ideal candidate for this laminoplasty procedure.”
“The instrumentation was easy to work with and allowed for predictable placement of the plate and screws,” continued Dr. Orndorff. “The plate’s arched radius is ideal for spinal canal expansion, and the foot on the plate provided effective initial stability. It is also possible to contour and trim the plate to accommodate variable patient anatomy.”
“The Integra Laminoplasty system complements and expands our posterior cervical portfolio and offers surgeons an anatomic solution for laminoplasty procedures. We look forward to continued success and growth in this market,” said Brian Larkin, President-Spine.
Source: Integra Lifesciences Holdings Corporation, Globe Newswire